Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study
第一作者单位:[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China[2]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China[3]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China[4]Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China[5]Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China[6]Shanghai First Peoples Hosp, Shanghai, Peoples R China[7]Zhejiang Univ Hosp, Hangzhou, Zhejiang, Peoples R China[8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[9]Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China[10]Nanfang Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China[11]Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China[12]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China[13]Liuzhou Workers Hosp, Liuzhou, Peoples R China[14]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China[15]Chinese Peoples Liberat Army PLA Gen Hosp, Beijing, Peoples R China[16]Shandong Linyi Tumor Hosp, Linyi, Shandong, Peoples R China[17]Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Gastrointestinal Oncol,Canc Hosp & Inst, Beijing, Peoples R China[18]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China[19]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China[20]China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China
推荐引用方式(GB/T 7714):
Wang Fenghua,Wei Xiao-Li,Feng Ji Feng,et al.Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):doi:10.1200/JCO.2019.37.15_suppl.6017.
APA:
Wang, Fenghua,Wei, Xiao-Li,Feng, Ji Feng,Li, Qi,Xu, Nong...&Xu, Rui-hua.(2019).Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA:
Wang, Fenghua,et al."Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)